Director/PDMR Dealing

Futura Medical PLC

17 January 2024

 

17 January 2024

 Futura Medical plc

("Futura" or the "Company")

Director/PDMR Dealing

Futura Medical plc (AIM: FUM), the pharmaceutical company developing innovative sexual health products, today announces that it has been notified that James Barder and his spouse, Charlotte Barder have gifted in aggregate 20,000 Ordinary Shares to a family member as part of inheritance and tax planning.

Following this transaction James Barder's interests in Ordinary Shares is 1,420,972 Ordinary Shares, representing approximately 0.5% of the Company's issued share capital.

ENDS

For further information please contact:

Futura Medical plc

James Barder, Chief Executive Officer

Angela Hildreth, Finance Director and COO

Email: [e-mail]

Tel: [phone]

www.futuramedical.com

Nominated Adviser and Sole Broker:

Liberum

Phil Walker/ Richard Lindley/ Ben Cryer

Tel: [phone]

For media enquiries please contact:

Optimum Strategic Communications

Nick Bastin / Jonathan Edwards / Elena Bates

Email: [e-mail]

Tel: [phone]

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing innovative products based on its proprietary, transdermal DermaSys® technology.

MED3000, the Company's breakthrough treatment for erectile dysfunction ("ED") has a unique evaporative mode of action and is clinically proven as an effective topical treatment for adult men with ED, with a key claim of "Helps you get an erection within 10 minutes". Eroxon® is available Over the Counter ("OTC") without a doctor's prescription. www.eroxon.com.

MED3000 is being manufactured and commercialised under the brand name Eroxon® and has been granted marketing authorisation by the FDA in the US, CE marked in Europe, UKCA marked in the UK and is gaining regulatory approval in a growing number of countries across the world. Futura has commercial agreements with Haleon for the US market and Cooper Consumer Health for Europe.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	James Barder
2	Reason for the notification
a)	Position/status	Director/ PDMR
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Futura Medical plc
b)	LEI	21380053QLT46UNV2303
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 0.2p each GB0033278473
b)	Nature of the transaction	1.     Transfer to PCA 2.     Transfer to family member
c)	Price(s) and volume(s)	Price(s) Volume(s) 1. nil 10,000 2. nil 10,000
d)	Aggregated information - Aggregated volume - Price	Not applicable
e)	Date of the transaction	17 January 2024
f)	Place of the transaction	Outside of trading venue

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Charlotte Barder
2	Reason for the notification
a)	Position/status	PCA of James Barder
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Futura Medical plc
b)	LEI	21380053QLT46UNV2303
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 0.2p each GB0033278473
b)	Nature of the transaction	1.     Receipt of shares from PCA 2.     Transfer to family member
c)	Price(s) and volume(s)	Price(s) Volume(s) 1. nil 10,000 2. nil 10,000
d)	Aggregated information - Aggregated volume - Price	Not applicable
e)	Date of the transaction	17 January 2024
f)	Place of the transaction	Outside of trading venue

 

END